Sweden's Peptonic Medical Q2 sales drop, gross margin narrows

Peptonic Medical AB

19/08/2026 07:10

Overview
Sweden women's health self-care maker's Q2 sales fell sharply yr/yr
Q2 gross margin dropped to 60% from 97% a year ago
Company raised SEK 7.5 mln via warrants, strengthening liquidity and reducing debt

Outlook
Company says focus is on product development, increased sales and brand building going forward
Peptonic to continue developing products, building partnerships and pursuing long-term growth
Company says process to update Vernivia CE marking continues, enabling potential relaunch

Result Drivers
US PARTNERSHIP LAUNCH - Co completed first commercial delivery under US partnership, marking a milestone in international expansion
NEW PRODUCT LAUNCHES - Co broadened its offering with launches in intimate wipes, moisturizing cream, and a dietary supplement
COST BASE REDUCTION - Co said it now has a lower cost base and more focused business after restructuring

Company press release: ID:nWkrbqljSp

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Sales
 
SEK 2.36 mln
 
Q2 Gross Margin
 
60.00%
 
Q2 Gross Profit
 
SEK 1.42 mln
 

Reuters Recommended Reads
Aug 18 - Sweden's OssDsign Q2 sales rise 2.4% gross margin falls
Aug 19 - Denmark's Lundbeck Q2 revenue rises 7% driven by Vyepti and Rexulti

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)